GSA Capital Partners’s Capricor Therapeutics CAPR Stock Holding History

GSA Capital Partners’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-215,675	Closed	-$1.55M	–	1694
2025 Q3	$1.55M	Buy	+215,675	New	+$1.59M	0.13%	167
2025 Q1	–	Sell	-18,243	Closed	-$252K	–	1685
2024 Q4	$252K	Buy	+18,243	New	+$320K	0.02%	1304
2024 Q3	–	Sell	-27,330	Closed	-$130K	–	1622
2024 Q2	$130K	Buy	+27,330	New	+$152K	0.01%	1504
2024 Q1	–	Sell	-32,970	Closed	-$161K	–	1635
2023 Q4	$161K	Sell	32,970 -10,835	-25%	-$35.3K	0.01%	1361
2023 Q3	$150K	Buy	43,805 +25,915	+145%	+$146K	0.01%	1341
2023 Q2	$86K	Buy	+17,890	New	+$78.6K	0.01%	1389
2021 Q4	–	Sell	-96,632	Closed	-$388K	–	1436
2021 Q3	$388K	Sell	96,632 -15,732	-14%	-$71.6K	0.04%	853
2021 Q2	$576K	Buy	112,364 +98,043	+685%	+$415K	0.06%	541
2021 Q1	$67K	Sell	14,321 -64,770	-82%	-$373K	0.01%	1019
2020 Q4	$271K	Buy	+79,091	New	+$343K	0.04%	798

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's CAPR Position: Q4 2025 in Review

GSA Capital Partners sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 215,675 shares — an estimated $1.55M sold.

GSA Capital Partners first reported a position in CAPR in Q4 2020 and held it in 10 quarters. The position peaked at $1.55M in Q3 2025. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

GSA Capital Partners reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 215,675 Capricor Therapeutics shares in Q4 2025, an estimated $1.55M.
GSA Capital Partners first reported a position in Capricor Therapeutics in Q4 2020 and held it in 10 quarters.
GSA Capital Partners's Capricor Therapeutics position peaked at $1.55M in Q3 2025.
132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.